Outcomes of Phase II Clinical Trials with Single-Agent Therapies in Advanced/Metastatic Non–Small Cell Lung Cancer Published between 2000 and 2009

Abstract

Purpose: We analyzed the outcomes of single-agent phase II clinical trials in non-small cell lung cancer (NSCLC) to determine trial parameters that predicted clinical activity.Exoerimental Design: Data on response rate (RR), progression-free survival (PFS), and overall survival (OS) from all English language, single-agent phase II trials in advanced/metastatic NSCLC indexed by PubMed (January 2000 through December 2009) were abstracted.Results: A total of 143 single-agent phase II trials (7,701 patients) were identified. The median RR was 10%, PFS 2.8 months, and OS 7.6 months. RR and PFS correlated with OS (r ¼ 0.46, P < 0.001, r ¼ 0.52, P < 0.001, respectively) and RR correlated with PFS (r ¼ 0.61, P < 0.001). Treatment arms enriched for patients with molecular targets had a higher median RR (48.8% vs. 9.7%, P ¼ 0.005), longer median PFS (6 vs. 2.8 months, P ¼ 0.005), and OS (11.3 vs. 7.5 months, P ¼ 0.05) as compared with those of unselected patients. In multivariate analysis, only studies enriched for patients with molecular targets or including drugs that eventually gained FDA/EMA approval were associated with a higher RR, and longer PFS/OS.Conclusions: In phase II trials in NSCLC, RR and PFS correlated with OS. Studies enriched for patients with putative molecular drug targets were associated with higher therapeutic benefit as compared with those of unselected populations.

Next generation sequencing demonstrates association between tumor suppressor gene aberrations and poor outcome in patients with cancer

“…Further, a Cox regression analysis showed that being treated with a personalized strategy was an independent factor predicting a longer best PFS (median 10.3 vs. 7 months, P D 0.046) ( Table 4), consistent with several other studies demonstrating that adopting a personalized approach to treat cancer patients improved clinical outcomes. 1,38,39 Our study has several important limitations. The analysis was retrospective and included different types of cancer, although the latter might infer that the results are generalizable across tumor types.…”

RECIST 1.1—Update and clarification: From the RECIST committee

“…The RECIST 1.1 paper has been cited 3881 times as of December 2015 Web of Science. Endpoints categorized by the RECIST criteria have been used as either primary or supportive data for regulatory approval of new therapeutics by both the FDA and EMA [4]. RECIST provides a standardized set of rules for response assessment using tumour shrinkage, based upon imaging modalities that are globally available and interpretable by most clinicians.…”

Molecular landscape of pancreatic cancer: implications for current clinical trials

“…[18–20] Further, a meta-analysis of the NSCLC literature showed responses of 49% when targeted treatments were matched to the appropriate subgroup of patients, but only 9.7% when unselected populations were treated. [21]…”